Discovery of tumor specific antigens in acute myeloid leukemia.

We performed RNA-Seq and mass spectrometry (MS) on the immunopeptidome of 19 human primary AML samples and discovered a set of 58 tumor specific antigens (TSA) that could serve to design an anti-AML immunotherapy. Four proteogenomic approaches were used to create cancer-specific MS databases. Peptide identifications were made on the samples used for RNA-Seq and database construction. Various bioinformatic approaches were then performed to establish the TSA nature of the peptides identified by MS. Data reported here are paired-end stranded RNA-sequencing (R1 map on reverse strand and R2 on forward strand) of the 19 AML samples at a coverage >120M reads / sample. MS data are freely available on PRIDE (PXD018542 and 10.6019/PXD018542).